<DOC>
	<DOCNO>NCT00462670</DOCNO>
	<brief_summary>To evaluate efficacy safety 7-day repeated oral administration OPC-41061 15 mg placebo congestive heart failure ( CHF ) patient extracellular volume expansion despite use conventional diuretic .</brief_summary>
	<brief_title>A Double-blind , Placebo-controlled Study OPC-41061 Treatment Cardiac Edema ( Congestive Heart Failure )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Edema , Cardiac</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Subjects receive one follow diuretic treatment ( include subject schedule start treatment runin observation period , 1 ) A loop diuretic daily dosage equivalent 40 mg furosemide , 2 ) Concomitant administration loop diuretic thiazide diuretic ( dos ) , 3 ) Concomitant administration loop diuretic antialdosterone drug ( dos ) 2 . CHF patient low limb edema , jugular venous distention , pulmonary congestion due extracellular volume expansion Patients pulmonary congestion enrol pulmonary congestion confirm chest xray take within 14 day prior screen examination . 3 . Male female subject age 20 old young 85 ( time inform consent ) 4 . Subjects able stay study site day start runin observation period completion postdosing examination 2 ( 7 10 day final study drug administration ) 5 . Subjects capable give informed consent participate study free 1 . Subjects acute heart failure 2 . Subjects assist circulation device 3 . Subjects follow complication symptom : ( 1 ) Suspected decrease circulatory blood flow , ( 2 ) Hypertrophic cardiomyopathy ( dilated phase ) , ( 3 ) Cardiac valve disease significant heart valve stenosis , ( 4 ) Hepatic coma 4 . Subjects develop acute myocardial infarction within 30 day prior screen examination 5 . Subjects definite diagnosis active myocarditis amyloid cardiomyopathy 6 . Subjects follow complication symptom : ( 1 ) Diabetes mellitus poorly control blood glucose , ( 2 ) Anuria , ( 3 ) Urination impair due urinary tract stricture , urinary calculus , tumor urinary tract , cause 7 . Subjects history follow disease : ( 1 ) Sustained ventricular tachycardia ventricular fibrillation within 30 day prior screen examination patient without implanted defibrillator , ( 2 ) Cerebrovascular disorder within 6 month prior screen examination ( asymptomatic cerebral infarction ) , ( 3 ) Hypersensitivity idiosyncratic reaction benzazepine derivative mozavaptan hydrochloride benazepril hydrochloride . 8 . Subjects obese [ body mass index ( BMI , body weight ( kg ) /height ( ) 2 exceed 35 ] 9 . Patients supine systolic blood pressure exceed 90 mmHg 10 . Subjects follow abnormal laboratory value : ( 1 ) Total bilirubin exceed 3.0 mg/dL , ( 2 ) serum creatinine exceed 3.0 mg/dL , ( 3 ) serum sodium exceed 147 mEq/L , ( 4 ) serum potassium exceed 5.5 mEq/L 11 . Patients unable take oral medication 12 . Female subject pregnant , possibly pregnant , lactate , plan become pregnant 13 . Subjects receive investigational drug OPC41061 within 30 day prior screen examination 14 . Subjects previously participate study OPC41061 receive OPC41061 15 . Subjects otherwise judge investigator subinvestigator inappropriate inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Cardiac edema</keyword>
	<keyword>OPC-41061</keyword>
	<keyword>Vasopressin antagonist</keyword>
</DOC>